Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer(ProVent) | completed | Phase 3 | 532 | DendreonINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03635489 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Oct 3, 2024 |
| clinicaltrials |
| NCT05600322 | Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer | completed | Phase 3 | 158 | PhotocureINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT00365105 | Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer | completed | Phase 3 | 261 | Radiation Therapy Oncology GroupNETWORK | 1 | Sep 20, 2024 | clinicaltrials |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | terminated | Phase 3 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 8 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05613023 | A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT(PACE-NODES) | recruiting | Phase 3 | 1,128 | Institute of Cancer Research, United KingdomOTHER | 3 | Sep 19, 2024 | clinicaltrials |
| NCT06592326 | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 460 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601205 | Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.(2F) | completed | Phase 2 / Phase 3 | 125 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer(MEDCARE) | recruiting | Phase 3 | 246 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT01272050 | Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery | completed | Phase 3 | 350 | Swiss Cancer InstituteOTHER | 3 | Aug 28, 2024 | clinicaltrials |
| NCT03056638 | Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | terminated | Phase 3 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures | terminated | Phase 3 | 13 | University of California, IrvineOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 3 | 104 | Hinova Pharmaceuticals USA, Inc.INDUSTRY | 14 | Aug 19, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06394492 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | recruiting | Phase 3 | 440 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT06542549 | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | not yet recruiting | Phase 3 | 100 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT05764044 | Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer(AddChemo) | recruiting | Phase 3 | 365 | Hospital do CoracaoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05822934 | Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer | unknown | Phase 3 | 20 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 157 | Ferring PharmaceuticalsINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)(CALLA) | completed | Phase 3 | 770 | AstraZenecaINDUSTRY | 15 | Jul 26, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT05924776 | Plasmodium Immunotherapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 / Phase 3 | 30 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03389451 | 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer | completed | Phase 2 / Phase 3 | 30 | Michael Graham PhD, MDOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05352178 | Metastasis-directed Therapy for Oligorecurrent Prostate Cancer(SPARKLE) | recruiting | Phase 3 | 873 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05847348 | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | unknown | Phase 3 | 110 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | not yet recruiting | Phase 3 | 420 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03751124 | Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 229 | Myovant Sciences GmbHINDUSTRY | 8 | Jun 25, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT05799248 | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | unknown | Phase 3 | 113 | MidLantic UrologyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT05622162 | Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7(MIP7) | unknown | Phase 3 | 106 | ITEL Telecomunicazioni SrlINDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT03412890 | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 477 | Myovant Sciences GmbHINDUSTRY | 9 | May 9, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT04684628 | 68Ga-PSMA PET/CT in Prostate Cancer | suspended | Phase 3 | 500 | University of SaskatchewanOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05027776 | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | recruiting | Phase 3 | 1,348 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06350825 | Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03940196 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | completed | Phase 3 | 540 | NovoCure Ltd.INDUSTRY | 13 | Mar 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 8, 2024source: clinicaltrials